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Background:  During coronary anastomosis in off-pump coronary artery bypass surgery (OPCAB), hemodynamic 
alternations can be induced by impaired diastolic function of the right ventricle. This study was designed to examine 
the effect of milrinone on right ventricular function and early outcomes in patients undergoing OPCAB.
Methods:  Forty patients undergoing OPCAB were randomly assigned in a double-blind manner to receive either 
milrinone (milrinone group, n = 20) or normal saline (control group, n = 20). Hemodynamic variables were measured 
after pericardiotomy (T1), 5 min after stabilizer application for anastomosis of the left anterior descending coronary 
artery (LAD, T2), the obtuse marginalis branch (OM, T3), the right coronary artery (RCA, T4), 5 min after sternal 
closure (T5), and after ICU arrival. The right ventricular ejection fraction (RVEF) and right ventricular volumetric 
parameters were also measured using the thermodilution technique. For evaluation of early outcomes, the 30-day 
operative mortality and morbidity risk models were used.
Results:  There was no significant difference in hemodynamic variables, including mean arterial pressure, between 
the 2 groups, except for the cardiac index and RVEF. The cardiac index and RVEF were significantly greater at T3 in 
the milrinone group than in the control group.
Conclusions:  Continuous infusion of milrinone demonstrated a beneficial effect on cardiac output and right 
ventricular function in patients undergoing OPCAB, especially during anastomosis of the graft to the OM artery, and 
it had no adverse effect on early outcomes.  (Korean J Anesthesiol 2010; 59: 92-98)
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Introduction
    Off-pump coronary artery bypass surgery (OPCAB) is widely 
performed for its benefit in reducing complications from 
cardiopulmonary bypass [1-3]. However, since the surgical 
method moves the pumping heart and limits movement of 
the surgery site with a tissue stabilizer, it can cause serious 
hemodynamic changes [4,5]. For example, the function of both 
ventricles declines due to pressure on the heart during OPCAB 
via diastolic dysfunction of the right ventricle due to pressure 
[6,7].
    Milrinone, a phosphodiesterase III inhibitor, prevents degra-
dation of cyclic adenosine monophosphate in cardiac myocytes 
to increase contractile force of the heart muscle, and it relaxes 
the vascular smooth muscle to reduce systemic vascular 
resistance [8]. Milrinone helps patients avoid cardiopulmonary 
bypass by increasing heart function. It also enhances cardiac 
contractility while not increasing oxygen requirements, 
unlike dobutamine, and prevents vasospasm during coronary 
anastomosis [9]. In an animal study in canines with pulmonary 
hypertension, milrinone significantly improved right ventricular 
function and reduced pulmonary vascular resistance to 
improve pulmonary blood flow [10]. Milrinone also prevents 
reduced cardiac output and mixed venous oxygen saturation in 
OPCAB [11], and studies on patients with low right ventricular 
function show that milrinone increases the cardiac index while 
reducing systemic vascular resistance, showing a beneficial role 
in improving right ventricular function [12]. 
    There is no research on the effects of milrinone on hemo-
dynamic changes or even on early intensive care unit (ICU) 
outcomes during and after OPCAB. Lowered function of 
the right ventricle accompanied by heart failure increases 
the mortality rate [13-15], but no study has been conducted 
in OPCAB patients. We therefore evaluated the impact of 
continuous milrinone infusion using a multi-lumen cardiac 
thermodilution catheter on hemodynamic changes, right 
ventricular function, and early outcome hemodynamics.
Materials and Methods 
    This study was authorized by the Institutional Review 
Board and was conducted with OPCAB patients after written 
consent, before giving them anesthetic. A pilot study showed 
that continuous infusion of milrinone reduced the right 
ventricular ejection fraction (RVEF) by 20% during anastomosis 
of the obtuse marginal branch. This result was considered 
meaningful, and when setting the effect size at 0.95, α error 
at 0.05, and β power at 0.8, 19 patients are required for each 
group. Considering a dropout rate of 5% from the authors’ 
other clinical experiences, the studies were conducted with 20 
patients in each group, 40 in total. 
    Exclusion criteria included left or right ventricular ejection 
fraction of less than 40% from the transthoracic echocardiogram 
before surgery, valvular heart disease, severe cerebral or renal 
dysfunction, or emergency surgery. Patients with stenosis 
at more than 3 coronary arteries were selected. An hour 
before arriving at the operating rooms, all patients received 
an intramuscular injection of morphine, 0.05-0.1 mg/kg, as 
preliminary anesthesia, and other drugs, except digoxin and 
diuretics, as normal. After arriving at the operating room, 
the induction of lead II and V5 was continuously monitored 
by 5-leads electrocardiography, and a catheter was inserted 
by radial artery puncture for continuous monitoring of 
hemo  dynamics and arterial blood sampling. A pulmonary 
catheter (Swan-Ganz CCOmbo
Ⓡ CCO/SvO2/CEDV, Edwards 
Lifesciences LLC, Irvine, CA, USA), which can continuously 
monitor cardiac output of the right internal jugular vein, mixed 
venous oxygen saturation, the right ventricular ejection fraction, 
and right ventricular end-diastolic volume index, was inserted 
through an 9F introducer (AVA HF, Edwards Lifesciences, CA, 
USA) and monitored using a computerized monitoring system 
(Vigilance
Ⓡ CCO/SvO2/CEDV Monitor, Edwards Lifesciences, 
CA, USA). 
    For inducing anesthesia, endotracheal intubation was 
performed after giving intravenous injections of midazolam 
2.5 mg, sufentanil 1.5-3.0 μg/kg, and rocuronium bromide 50 
mg. To maintain anesthesia, sufentanil (0.5-1.5 μg/kg/h) and 
vecuronium were continuously administered intravenously 
with 50% oxygen and 50% medical air, as well as sevoflurane 
with an end-tidal concentration of 0.2-0.4 vol%, and controlled 
ventilation was conducted to set the end-tidal CO2 tension at 
30-35 mmHg. After inducing anesthesia, isosorbide dinitrate 
(0.5 μg/kg/min) was administered to prevent myocardial 
ischemia and coronary vasospasm, and a transesophageal 
echocardiography probe was inserted to continuously monitor 
cardiac movement from a short-axis mid-papillary muscle 
view, which shows the left ventricular papillary muscle, or a 
4- or 2-chamber view if monitoring was difficult. Moreover, 
the temperature of the operating room was kept at over 20
oC. 
To maintain blood temperature, as measured by pulmonary 
artery catheter, at over 35.5
oC, a warm mattress, warming 
blanket, infusion blood warmer, and humidifier with heated 
wire breathing circuit were used. During dissection of the 
internal mammary artery for a graft after median sternotomy, 
an infusion solution of 1,500-2,000 ml was injected for 2 
hours to maintain preload of the heart, and then the infusion 
solution was injected intravenously at a speed of 6-8 ml/kg/
hr to keep the volume at a similar level as post-anesthesia 
induction while monitoring the left ventricular end-diastolic 
volume from echocardiography. After performing sternotomy, 94 www.ekja.org
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patients received saline (n=20, controls) or milrinone 
(n=20, Sanofi, Korea) 0.5 μg/kg/min during coronary artery 
anastomosis. After finishing the dissection of the internal 
mammary artery, heparin 1 mg/kg was injected intravenously 
and activated coagulation time was maintained at over 250 
seconds. The heart was elevated using a pericardial suture and 
gauze and rotated to clear vision, and then the movement of 
blood vessels for vascular anastomosis was prevented with 
the Octopus Tissue Stabilization system
Ⓡ, Medtronic Inc. 
USA. Vascular anastomosis was started with the left anterior 
descending artery (LAD), obtuse marginal branch (OM), and 
right coronary artery (RCA) to the posterior descending artery 
(PDA); and a shunt (Florester
Ⓡ, Bio-Vascular Co., USA) inside 
the coronary artery was used to maintain coronary flow during 
the operation. All procedures were performed by the same 
cardiac surgeon and anesthesiologist blinded to the treatment 
groups. For hypotension during proximal anastomosis of 
each coronary artery, the Trendelenburg position at 15-
20
o was taken, and for hypotension during elevating heart or 
anastomosis, norepinephrine (8 μg/ml) was given to keep the 
mean arterial pressure over 70 mmHg. A measurement of the 
variables was conducted after pericardiotomy (T1, base value), 
every 5 minutes after attaching a cardiac tissue stabilizer for 
anastomosis of the left anterior descending artery, obtuse 
marginal and posterior descending artery of the right coronary 
artery (each LAD:T2, OM:T3 and PDA:T4) and after performing 
sternum closure (T5); and the time of measuring hemodynamic 
variables in the intensive care unit was immediately, 6 hours 
after, and 12 hours after arrival in the intensive care unit. 
Variables included heart rate, mean arterial pressure, central 
venous pressure, mean pulmonary artery pressure, pulmonary 
capillary wedge pressure, mixed venous oxygen saturation, 
cardiac output, right ventricular volume index, and right 
ventricular ejection fraction. The systemic vascular resistance 
index and pulmonary vascular resistance index were calculated 
while recording the administered volume of norepinephrine. 
Also, to monitor and compare early outcomes, we recorded 
permanent cerebral infarction for 30 days after the operation, 
as suggested by the Society of Thoracic Surgeons, renal 
insufficiency, mechanical ventilation lasting more than 48 
hours, deep sternal infection, re-operation, and the mortality 
rate [16]. Renal failure was defined as when serum creatine 
increased more than 2.0 after the operation was performed, 
when it increased more than 50% compared to the base value 
before the operation, or when dialysis was required. SPSS 12.0 
(SPSS Inc., Chicago, IL, USA) was used for statistical analysis, 
and all values are given as the average ± standard deviation or 
the number of patients. To compare groups, an independent 
t-test was used for continuous data, and Fisher’s exact test 
and the chi-square test were used to evaluate categorical data. 
Comparisons between base and measured values over time was 
conducted with a paired t-test after setting the estimated value 
as the control value after performing pericardiotomy. P < 0.05 
was considered significant.
Results
    OPCAB was performed successfully without transition to 
emergency cardiopulmonary bypass. There were no significant 
statistical differences between the 2 groups for gender, age, 
medical history of diabetes and hypertension, drug admini-
stration, or left ventricle ejection rate (Table 1). The total operation 
time, coronary artery anastomosis, and total norepinephrine 
volume were similar for both groups (Table 2). Heart movement 
and stabilization for anastomosis did not require treatment of 
arrhythmia. 
    Cardiac index decreased in controls during OM anastomosis, 
whereas milrinone treatment increased it (P < 0.05, Table 3). 
Milrinone also blocked the increase in pulmonary vascular 
Table 1. Patient Characteristics
Control group
(n = 20)
Milrinone group
(n = 20)
Age (yr)
Sex (M/F)
Height (cm)
Weight (kg)
BSA (m
2)
Left ventricular ejection fraction (%)
Comorbid risk factors (n)
   Hypertension
   Diabetes mellitus
   Previous myocardial infarction
   Transient ischemic accident
Preoperative medication (n)
   Beta blocker
   Calcium channel antagonist
   ACE inhibitor
   Digoxin
   Diuretics
64.1 ± 9.9
11/9
158.3 ± 25.4
 71.2 ± 24.1
 1.7 ± 0.1
 51.1 ± 13.3
11
  7
  3
  2
13
16
12
  1
  2
67.0 ± 9.2
12/8
161.2 ± 11.8
 66.6 ± 14.9
 1.6 ± 0.2
 45.4 ± 14.0
11
  9
  4
  2
14
15
11
  0
  2
All values are presented as number of patients or mean ± SD. M/
F: male/female, BSA: body surface area, ACE inhibitor: angiotensin 
converting enzyme inhibitors.
Table 2. Surgical Data and Amount of Norepinephrine during 
Coronary Artery Anastomosis
Control group Milrinone group
Number of graft (n)
Duration of surgery (min)
Anastomosis time (min)
Norepinephrine (µg)
3.1 ± 0.9
285.1 ± 25.4
85.5 ± 31.0
301.4 ± 297.4
3.4 ± 1.0
309.5 ± 31.2
93.2 ± 27.1
289.9 ± 276.2
All values are presented as mean ± SD.95 www.ekja.org
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resistance index during LAD and OM anastomosis (P < 0.05, 
Table 3). Milrinone also increased the right ventricular ejection 
fraction during anastomosis, but did not change other variables 
(P < 0.05, Table 4). During anastomosis, mean arterial pressure 
remained steady but heart rate increased with time. Pulmonary 
artery pressure increased during anastomosis in controls, but 
only during PDA anastomosis in the milrinone group. Central 
venous pressure was increased for both groups during PDA 
anastomosis. Mixed venous oxygen saturation decreased in 
the milrinone group during OM anastomosis, and in both 
groups during PDA anastomosis. The cardiac index decreased 
significantly compared to baseline during OM anastomosis 
for controls, whereas the systemic vascular resistance index 
and pulmonary vascular resistance index were increased 
significantly during OM anastomosis (P < 0.05, Table 3).
    The hemodynamic variables checked immediately after arrival 
in the ICU, 6 hours after arriving, and 12 hours after arriving 
did not show significant gaps between the groups (Table 5), 
and there were no early deaths; both groups showed similar 
rates of myocardial infarction, cerebral infarction, renal 
failure, mechanical ventilation lasting more than 48 hours, re-
operation, and infections (Table 6).
Discussion
    The study focused on the effect of milrinone infusion on right 
ventricular function during coronary anastomosis and early 
outcomes in patients undergoing OPCAB. Milrinone infusion 
prevented reductions in the right ventricular ejection fraction 
during anastomosis of the obtuse marginal artery, on the 
Table 3. Changes in Hemodynamic Variables during Coronary Artery Anastomosis
Group T1 T2 T3 T4 T5
HR (Beats/min)
MAP (mmHg)
MPAP (mmHg)
CVP (mmHg)
PCWP (mmHg)
SvO2 (%)
CI (L/min/m
2)
SVRI (dyn·s/cm
5/m
2)
PVRI (dyn·s/cm
5/m
2)
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
70 ± 16
72 ± 15
84 ± 13
82 ± 12
20 ± 8
19 ± 4
10 ± 5
9 ± 3
16 ± 8
13 ± 3
77 ± 4
75 ± 2
2.7 ± 0.4
2.5 ± 0.6
866 ± 355
913 ± 263
64 ± 50
63 ± 26
77 ± 16
†
80 ± 14
†
78 ± 10
74 ± 12
25 ± 6
†
21 ± 7
9 ± 2
7 ± 2
18 ± 6
14 ± 4
77 ± 7
71 ± 7
2.6 ± 0.5
2.9 ± 0.4
1,053 ± 260
756 ± 293
91 ± 51
49 ± 38*
78 ± 15
†
88 ± 15
†
78 ± 11
73 ± 10
24 ± 9
†
20 ± 7
12 ± 6
9 ± 3
17 ± 9
13 ± 4
73 ± 9
65 ± 11
†
2.0 ± 0.4
†
2.9 ± 0.4*
1,208 ± 325
†
839 ± 304
125 ± 33
†
79 ± 44*
78 ± 13
†
89 ± 9
†
78 ± 8
75 ± 9
27 ± 5
†
23 ± 6
†
15 ± 2
†
14 ± 2
†
19 ± 4
16 ± 4
58 ± 6
†
66 ± 9
†
2.4 ± 0.7
2.8 ± 0.7
1,076 ± 272
809 ± 246
94 ± 44
82 ± 34
73 ± 15
89 ± 10
80 ± 9
73 ± 17
20 ± 6
18 ± 5
10 ± 3
9 ± 2
14 ± 5
13 ± 2
73 ± 9
70 ± 4
3.0 ± 0.7
2.9 ± 0.6
987 ± 268
851 ± 32
62 ± 29
57 ± 17
All values are presented as mean ± SD. HR: heart rate, MAP: mean arterial pressure, MPAP: mean pulmonary arterialpressure, CVP: central 
venous pressure, PCWP: pulmonary capillary wedge pressure, SvO2: mixed venous oxygen saturation, CI: cardiac index, SVRI: systemic vascular 
resistance index, PVR: pulmonary vascular resistance index, T1: after pericardiotomy, T2, T3 and T4: 5 minutes after stabilizer application 
for anastomosis of the left anterior descending coronary artery (T2), obtuse marginalis artery (T3), and posterior descending artery of right 
coronary artery (T4), T5: 5 minutes after sternum closure. *P < 0.05 between the two groups, 
†P < 0.05 compared to values at T1 in each group.
Table 4. Right Ventricular Volumetric Data during Coronary Artery Anastomosis
T1 T2 T3 T4 T5
RVEF (%)
RVESVI (ml/m
2)
RVEDVI (ml/m
2)
Control
Milrinone
Control
Milrinone
Control
Milrinone
28 ± 6
27 ± 5
 90 ± 20
 98 ± 33
129 ± 18
129 ± 32
30 ± 8
29 ± 7
 91 ± 21
105 ± 37
131 ± 24
134 ± 41
23 ± 5
31 ± 6*
 85 ± 25
 79 ± 28
122 ± 24
114 ± 30
27 ± 5
29 ± 5
 84 ± 14
 98 ± 30
125 ± 16
127 ± 32
32 ± 8
31 ± 4
 88 ± 22
 93 ± 50
129 ± 21
125 ± 51
All values are presented as mean ± SD. RVEF: right ventricular ejection fraction, RVESVI: right ventricular end systolic volume index, RVEDVI: 
right ventricular end diastolic volume index, T1: after pericardiotomy, T2, T3 and T4: 5 minutesafter stabilizer application for anastomosis of 
the left anterior descending coronary artery (T2), obtuse marginalis artery (T3), and posterior descending artery of right coronary artery (T4), 
T5: 5 minutes after sternum closure. *P < 0.05 between the two groups.96 www.ekja.org
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posterior slope of the heart, and did not greatly influence early 
outcomes. OPCAB can reduce the incidence of complications 
related with external circulation, including pulmonary 
dysfunction, kidney injury, brain injury, and hematoma, 
but can cause hemodynamic instability when the heart is 
elevated and stabilized for the anastomosis [17,18]. Elevating 
the heart vertically to expose blood vessels for anastomosis 
decreases cardiac output and blood pressure and increases 
central venous pressure, but reducing central venous pressure 
with a pump that delivers blood to the pulmonary artery via 
cannulation of the right atrium increased right heart function 
and improved hemodynamic instability in animals [19]. 
Increasing ventricular preload by postural changes, including 
the head-down tilt position, helps maintain ventricular 
function [20]. Dysfunction of the right ventricle from stabilizer 
pressure can cause hemodynamic disorders during OPCAB, 
particularly during vascular anastomosis of the posterior border 
of the heart [21]. For most OPCAB patients, coronary artery 
anastomosis does not cause serious hemodynamic disorders, 
but obtuse marginal artery anastomosis on the posterior 
border of heart can decrease both right and left ventricle 
function [22,23]; milrinone infusion could block the decreases 
in cardiac index during obtuse marginal artery anastomosis 
and the right ventricular ejection fraction. Right ventricle 
function significantly influences left ventricle function through 
interdependence, and shows a close interrelationship with 
congestive heart failure and the short-and-long-term survival 
rate of OPCAB patients [13,14,24]. Milrinone improved RVEF 
by enhancing left ventricle function, increasing the cardiac 
index, and decreasing systemic vascular resistance, as well 
as improving right ventricular function by blocking increases 
in pulmonary vascular resistance. Milrinone increases the 
cardiac index for congestive heart failure patients at plasma 
concentrations of 66-427 ng/ml [25]. Continuous intravenous 
injection of milrinone at 0.5 μg/kg/min after bolus injection of 
50 μg/kg brought plasma concentrations up to 100 ng/ml, and 
the infusion rate was appropriate for the treatment of weaning 
of cardiopulmonary bypass [26]; the milrinone infusion rate of 
0.5 μg/kg/min produces plasma concentrations of 100-300 ng/
ml. A bolus loading of milrinone ,may cause hypotension [27], 
but continuous intravenous injection alone (without bolus) 
can produce effective plasma concentrations within an hour 
[28]. Milrinone injection was started after sternotomy and 
reached effective levels because it requires more than 1 hour 
from excoriating the internal mammal artery to coronary artery 
anastomosis. Although milrinone can induce hypotension and 
arrhythmia, we did not observe these side effects here. The 
RVEF, as estimated by a pulmonary artery catheter using the 
thermodilution method, reflects right ventricle function with 
high reliability and reproducibility [29,30]. Thermodilution may 
be more reliable than transesophageal echocardiography (TEE) 
[31] for measuring right ventricle function during surgery. 
The RVEF using a pulmonary artery catheter is sensitive to 
preload changes, but we did not detect differences in the 
right ventricular diastole volume index, a measure of preload. 
OPCAB patients have chronic ischemic heart disease due to a 
drastic decline of coronary artery blood flow to both ventricles, 
so transitioning the heart to the coronary artery site for 
anastomosis would worsen the function of both ventricles by 
reducing cardiac output [32]. In particular, because the obtuse 
marginal artery produces more functional disorders than other 
Table 5. ICU Hemodynamic Data
Group Arrival ICU 6 hr ICU 12 hr
HR (beats/min)
MAP (mmHg)
MPAP (mmHg)
CVP (mmHg)
PCWP (mmHg)
SvO2 (%)
CI (L/min/m
2)
SVRI (dyn·s/cm
5/m
2)
PVRI (dyn·s/cm
5/m
2)
RVEF (%)
RVESVI (ml/m
2) 
 
RVEDVI (ml/m
2)
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
Control
Milrinone
82 ± 15
84 ± 13
85 ± 13
81 ± 13
24 ± 9
21 ± 5
13 ± 5
12 ± 3
17 ± 8
14 ± 3
78 ± 4
73 ± 2
2.8 ± 0.4
2.9 ± 0.6
745 ± 326
790 ± 243
74 ± 50
63 ± 26
29 ± 3
31 ± 6
88 ± 21
90 ± 33
132 ± 18
129 ± 32
77 ± 16
81 ± 14
81 ± 11
78 ± 11
22 ± 7
24 ± 9
10 ± 2
9 ± 2
17 ± 6
13 ± 4
76 ± 8
74 ± 7
2.6 ± 0.3
3.0 ± 0.6
756 ± 312
772 ± 279
61 ± 51
59 ± 38
32 ± 8
33 ± 7
91 ± 21
112 ± 37
135 ± 27
134 ± 41
72 ± 15
79 ± 15
76 ± 13
75 ± 10
22 ± 9
24 ± 7
11 ± 6
9 ± 3
16 ± 9
13 ± 7
74 ± 9
70 ± 11
2.9 ± 0.4
3.4 ± 0.4
773 ± 225
812 ± 310
75 ± 33
70 ± 44
33 ± 5
34 ± 6
95 ± 27
89 ± 28
132 ± 24
144 ± 20
All values are presented as mean ± SD. ICU: intensive care unit, HR: 
heart rate, MAP: mean arterial pressure, MPAP: mean pulmonary 
arterial pressure, CVP: central venous pressure, PCWP: pulmonary 
capillary wedge pressure, SvO2: mixed venous oxygen saturation, 
CI: cardiac index, SVRI: systemic vascular resistance index, PVRI: 
pulmonary vascular resistance index, RVEF: right ventricular 
ejection fraction, RVESVI: right ventricular end systolic volume 
index, RVEDVI: right ventricular end diastolic volume index.
Table 6. 30-day Operative Morbidity Results
Control group  
(n = 20)
Milrinone group  
(n = 20)
Stroke
Renal failure
Prolonged ventilation
Reoperation
Sternal infection
1
2
2
0
0
0
1
2
1
1
All values are number of patients.97 www.ekja.org
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coronary arteries during anastomosis, intensive monitoring and 
treatment of ischemic heart disease is required to avoid declines 
in ventricle function [19]. Milrinone may therefore stabilize 
ventricle function during obtuse marginal artery anastomosis, 
as assessed by the RVEF and cardiac index via a pulmonary 
artery catheter. The Society of Thoracic Surgeons measures early 
OPCAB outcomes such as mortality rate within 30 days, stroke, 
renal failure, reoperation, continuous mechanical ventilation, 
and infection frequency of the sternum [16]. Both groups 
showed a similar complication rate, indicating that milrinone 
does not affect early outcomes. 
    One limitation of our research is that RVEF using a pulmonary 
artery catheter is very sensitive to preload and afterload, which 
may change based on patient position. Secondly, complication 
rates were similar in both groups, but larger studies are needed 
to confirm this. Thirdly, the time of obtuse marginal artery 
anastomosis may be less than 10 minutes on average, meaning 
that it is clinically meaningless for the ischemic preconditioning 
heart. Lastly, we only included patients with normal left 
ventricle function, and further work should include patients 
with abnormal ventricular function. 
    In conclusion, milrinone infusion during OPCAB surgery 
blocked reductions in RVEF during obtuse marginal artery 
anastomosis and maximal levels of hemodynamic instability 
with similar complication rates as controls. 
References
1. Buffolo E, de Andrade CS, Branco JN, Teles CA, Aguiar LF, Gomes 
WJ. Coronary artery bypass grafting without cardiopulmonary 
bypass. Ann Thorac Surg 1996; 61: 63-6.
2. Jansen EW, Gründeman PF, Borst C, Eefting F, Diephuis J, Nierich 
A, et al. Less invasive off-pump CABG using a suction device for 
immobilization: the ‘Octopus’ method. Eur J Cardiothorac Surg 
1997; 12: 406-12.
3. Hart JC, Spooner TH, Pym J, Flavin TF, Edgerton JR, Mack MJ, et al. 
A review of 1,582 consecutive Octopus off-pump coronary bypass 
patients. Ann Thorac Surg 2000; 70: 1017-20.
4. Cartier R, Blain R. Off-pump revascularization of the circumflex 
artery: technical aspect and short-term results. Ann Thorac Surg 
1999; 68: 94-9.
5. Jansen EW, Borst C, Lahpor JR, Gründeman PF, Eefting F, Nierich 
A, et al. Coronary artery bypass grafting without cardiopulmonary 
bypass using the octopus method: results in the first one hundred 
patients. J Thorac Cardiovasc Surg 1998; 116: 60-7.
6. Gründeman PF, Borst C, Verlaan CW, Meijburg H, Mouës CM, 
Jansen EW. Exposure of circumflex branches in the tilted, beating 
porcine heart: echocardiographic evidence of right ventricular 
deformation and the effect of right or left heart bypass. J Thorac 
Cardiovasc Surg 1999; 118: 316-23.
7. Nierich AP, Diephuis J, Jansen EW, Borst C, Knape JT. Heart 
displacement during off-pump CABG: how well is it tolerated? Ann 
Thorac Surg 2000; 70: 466-72.
8. Borow KM, Come PC, Neumann A, Baim DS, Braunwald E, 
Grossman W. Physiologic assessment of the inotropic, vasodilator 
and afterload reducing effects of milrinone in subjects without 
cardiac disease. Am J Cardiol 1985; 55: 204-9.
9. Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac 
surgery. Ann Thorac Surg 2002; 73: 325-30.
10. Chen EP, Bittner HB, Davis RD Jr, Van Trigt P 3rd. Milrinone 
improves pulmonary hemodynamics and right ventricular function 
in chronic pulmonary hypertension. Ann Thorac Surg 1997; 63: 814-21.
11. Kwak YL, Oh YJ, Shinn HK, Yoo KJ, Kim SH, Hong YW. Haemo-
dynamic effects of a milrinone infusion without a bolus in patients 
undergoing off-pump coronary artery bypass graft surgery. 
Anaesthesia 2004; 59: 324-31.
12. Lee JH, Oh YJ, Shim YH, Hong YW, Yi G, Kwak YL. The effect 
of milrinone on the right ventriclular function in patients with 
reduced right ventricular function undergoing off-pump coronary 
artery bypass graft surgery. J Korean Med Sci 2006; 21: 854-8.
13. Maslow AD, Regan MM, Panzica P, Heindel S, Mashikan J, 
Comunale ME. Precardiopulmonary bypass right ventricular 
function is associated with poor outcome after coronary bypass 
grafting in patients with severe left ventricular systolic dysfunction. 
Anesth Analg 2002; 95: 1507-18.
14. de Groote P, Millaire A, Foucher-Hossein C, Nugue O, Marchandise 
X, Ducloux G. Right ventricular ejection fraction is an independent 
predictor of survival in patients with moderate heart failure. J Am 
Coll Cardiol 1998; 32: 948-54.
15. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry 
GJ, et al. Effects of right ventricular ejection fraction on outcomes in 
chronic systolic heart failure. Circulation 2010; 121: 252-8.
16. Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, 
Chen A, et al. The Society of Thoracic Surgeons: 30-day operative 
mortality and morbidity risk models. Ann Thorac Surg 2003; 75: 
1856-64.
17. Lee JH, Abdelhady K, Capdeville M. Clinical outcomes and resource 
usage in 100 consecutive patients after off-pump coronary bypass 
procedures. Surgery 2000; 128: 548-55.
18. Nierich AP, Diephuis J, Jansen EW, van Dijk D, Lahpor JR, Borst C, 
et al. Embracing the heart: perioperative management of patients 
undergoing off-pump coronary artery bypass grafting using the 
octopus tissue stabilizer. J Cardiothorac Vasc Anesth 1999; 13: 123-9.
19. Porat E, Sharony R, Ivry S, Ozaki S, Meyns BP, Flameng WJ, et al. 
Hemodynamic changes and right heart support during vertical 
displacement of the beating heart. Ann Thorac Surg 2000; 69: 1188-91.
20. Gründeman PF, Borst C, van Herwaarden JA, Mansvelt Beck HJ, 
Jansen EW. Hemodynamic changes during displacement of the 
beating heart by the Utrecht Octopus method. Ann Thorac Surg 
1997; 63(Suppl 6): S88-92.
21. Mathison M, Edgerton JR, Horswell JL, Akin JJ, Mack MJ. Analysis of 
hemodynamic changes during beating heart surgical procedures. 
Ann Thorac Surg 2000; 70: 1355-60; discussion 1360-1.
22. Kim KB, Kang CH, Chang WI, Lim C, Kim JH, Ham BM, et al. Off-
pump coronary artery bypass with complete avoidance of aortic 
manipulation. Ann Thorac Surg 2002; 74: S1377-82.
23. Kwak YL, Oh YJ, Jung SM, Yoo KJ, Lee JH, Hong YW. Change in right 
ventricular function during off-pump coronary artery bypass graft 98 www.ekja.org
The effect of milrinone infusion on right ventricular function Vol. 59, No. 2, August 2010
surgery. Eur J Cardiothorac Surg 2004; 25: 572-7.
24. Gorcsan J 3rd, Murali S, Counihan PJ, Mandarino WA, Kormos RL. 
Right ventricular performance and contractile reserve in patients 
with severe heart failure. Assessment by pressure-area relations and 
association with outcome. Circulation 1996; 94: 3190-7.
25. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive 
inotropic and vasodilator actions of milrinone in patients with 
severe congestive heart failure. Dose-response relationships and 
comparison to nitroprusside. J Clin Invest 1985; 75: 643-9.
26. Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC Jr. Pharmacokinetics 
of intravenous milrinone in patients undergoing cardiac surgery. 
Anesthesiology 1994; 81: 616-22.
27. Lobato EB, Janelle GM, Urdaneta F, Martin TD. Comparison of 
milrinone versus nitroglycerin, alone and in combination, on 
grafted internal mammary artery flow after cardiopulmonary 
bypass: effects of alpha-adrenergic stimulation. J Cardiothorac Vasc 
Anesth 2001; 15: 723-7.
28. Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Pharmacodynamic 
effects of milrinone with and without a bolus loading infusion. Am 
Heart J 2001; 141: 266-73.
29. Perings SM, Perings C, Kelm M, Strauer BE. Comparative evaluation 
of thermodilution and gated blood pool method for determination 
of right ventricular ejection fraction at rest and during exercise. 
Cardiology 2001; 95: 161-3.
30. Urban P, Scheidegger D, Gabathuler J, Rutishauser W. Thermo-
dilution determination of right ventricular volume and ejection 
fraction: a comparison with biplane angiography. Crit Care Med 
1987; 15: 652-5.
31. Samuelsson S, Ehrenberg J, Settergren G. Clinical estimation 
of left and right ventricular volume with open chest compared 
with transesophageal echocardiography and fast-response 
thermodilution. J Cardiothorac Vasc Anesth 1995; 9: 670-5.
32. Biswas S, Clements F, Diodato L, Hughes GC, Landolfo K. Changes 
in systolic and diastolic function during multivessel off-pump 
coronary bypass grafting. Eur J Cardiothorac Surg 2001; 20: 913-7.